Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Non-cash Items (2017 - 2025)

Protalix BioTherapeutics (PLX) has 8 years of Non-cash Items data on record, last reported at $4.2 million in Q4 2024.

  • For Q4 2024, Non-cash Items rose 63.38% year-over-year to $4.2 million; the TTM value through Dec 2024 reached $4.2 million, up 63.38%, while the annual FY2024 figure was $4.2 million, 63.38% up from the prior year.
  • Non-cash Items reached $4.2 million in Q4 2024 per PLX's latest filing, up from $2.6 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $4.2 million in Q4 2024 and bottomed at $106875.0 in Q4 2020.
  • Average Non-cash Items over 5 years is $1.7 million, with a median of $1.2 million recorded in 2022.
  • Peak YoY movement for Non-cash Items: tumbled 79.92% in 2020, then skyrocketed 523.38% in 2022.
  • A 5-year view of Non-cash Items shows it stood at $106875.0 in 2020, then soared by 80.12% to $192500.0 in 2021, then surged by 523.38% to $1.2 million in 2022, then skyrocketed by 116.67% to $2.6 million in 2023, then soared by 63.38% to $4.2 million in 2024.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $4.2 million in Q4 2024, $2.6 million in Q4 2023, and $1.2 million in Q4 2022.